Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
IOVA

IOVA - Iovance Biotherapeutics Inc Stock Price, Fair Value and News

10.24USD-0.19 (-1.82%)Delayed

Market Summary

IOVA
USD10.24-0.19
Delayed
-1.82%

IOVA Stock Price

View Fullscreen

IOVA RSI Chart

IOVA Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-6.37

Price/Sales (Trailing)

2.4K

EV/EBITDA

-6.15

Price/Free Cashflow

-7.07

IOVA Price/Sales (Trailing)

IOVA Profitability

Operating Margin

-804.54%

EBT Margin

-38227.92%

Return on Equity

-66.13%

Return on Assets

-51.7%

Free Cashflow Yield

-14.14%

IOVA Fundamentals

IOVA Revenue

Revenue (TTM)

1.2M

IOVA Earnings

Earnings (TTM)

-449.7M

Earnings Growth (Yr)

-5.24%

Earnings Growth (Qtr)

2.9%

Breaking Down IOVA Revenue

Last 7 days

-6.6%

Last 30 days

-13.2%

Last 90 days

11.9%

Trailing 12 Months

37.6%

How does IOVA drawdown profile look like?

IOVA Financial Health

Current Ratio

4.63

IOVA Investor Care

Shares Dilution (1Y)

24.68%

Diluted EPS (TTM)

-1.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20230001.2M

Tracking the Latest Insider Buys and Sells of Iovance Biotherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 15, 2024
bilinsky igor
acquired
-
-
2,812
chief operating officer
Apr 15, 2024
graf finckenstein friedrich
acquired
-
-
2,812
chief medical officer
Apr 15, 2024
graf finckenstein friedrich
sold (taxes)
-16,967
11.89
-1,427
chief medical officer
Apr 15, 2024
vogt frederick g
sold (taxes)
-105,238
11.89
-8,851
interim ceo & general counsel
Apr 15, 2024
vogt frederick g
acquired
-
-
20,834
interim ceo & general counsel
Apr 15, 2024
bilinsky igor
sold (taxes)
-16,967
11.89
-1,427
chief operating officer
Mar 04, 2024
bilinsky igor
sold (taxes)
-123,588
16.96
-7,287
chief operating officer
Mar 04, 2024
vogt frederick g
acquired
-
-
41,662
interim ceo & general counsel
Mar 04, 2024
vogt frederick g
sold (taxes)
-194,175
16.96
-11,449
interim ceo & general counsel
Mar 04, 2024
graf finckenstein friedrich
sold (taxes)
-136,579
16.96
-8,053
chief medical officer

1–10 of 50

Which funds bought or sold IOVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-16.88
989,961
2,911,550
-%
May 16, 2024
Arete Wealth Advisors, LLC
reduced
-68.32
-742,943
1,015,170
0.09%
May 16, 2024
COMERICA BANK
added
2.76
44,228
94,878
-%
May 16, 2024
JANE STREET GROUP, LLC
added
95.4
10,883,800
15,132,200
-%
May 15, 2024
CAPTRUST FINANCIAL ADVISORS
added
41.04
453,001
741,356
-%
May 15, 2024
LMR Partners LLP
added
195
1,467,230
1,802,280
0.02%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
12,578
27,862
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
92.52
274,973
384,549
0.01%
May 15, 2024
PORTLAND INVESTMENT COUNSEL INC.
unchanged
-
90,000
212,000
0.06%
May 15, 2024
Mariner, LLC
added
1.75
113,789
246,901
-%

1–10 of 36

Are Funds Buying or Selling IOVA?

Are funds buying IOVA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IOVA
No. of Funds

Unveiling Iovance Biotherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 19, 2024
quogue capital llc
11.6%
3e+07
SC 13D/A
Mar 01, 2024
perceptive advisors llc
6.9%
19,221,743
SC 13G
Feb 14, 2024
point72 asset management, l.p.
0%
0
SC 13G/A
Feb 14, 2024
perceptive advisors llc
4.7%
11,979,415
SC 13G/A
Feb 13, 2024
vanguard group inc
8.91%
22,812,820
SC 13G/A
Feb 09, 2024
mhr fund management llc
6.9%
17,605,902
SC 13G/A
Jan 26, 2024
blackrock inc.
7.5%
19,071,756
SC 13G/A
Jan 25, 2024
state street corp
6.42%
16,424,388
SC 13G/A
Oct 27, 2023
quogue capital llc
15.84%
2.5e+07
SC 13D/A
Feb 17, 2023
point72 asset management, l.p.
4.6%
7,347,600
SC 13G

Recent SEC filings of Iovance Biotherapeutics Inc

View All Filings
Date Filed Form Type Document
May 17, 2024
DEFA14A
DEFA14A
May 10, 2024
S-8
Employee Benefits Plan
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
May 01, 2024
ARS
ARS
Apr 29, 2024
DEF 14A
DEF 14A
Apr 29, 2024
DEFA14A
DEFA14A
Apr 17, 2024
4
Insider Trading
Apr 17, 2024
4
Insider Trading
Apr 17, 2024
4
Insider Trading

Peers (Alternatives to Iovance Biotherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Iovance Biotherapeutics Inc News

Latest updates
GlobeNewswire17 hours ago
The Motley Fool10 May 202407:00 am
The Motley Fool28 Apr 202407:00 am
The Motley Fool17 Apr 202407:00 am

Iovance Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q2
Revenue20.8%715,000592,000469,000238,000
Cost Of Revenue-7,261,000-4,340,0002,050,000
Costs and Expenses-2.7%118,437,000121,738,000118,830,000110,324,000
  S&GA Expenses-100.0%-29,903,00026,964,00021,927,000
  R&D Expenses-8.8%79,783,00087,470,00087,526,00086,347,000
EBITDA Margin-1.6%-372-366--
Income Taxes19.9%-1,400,000-1,747,500-1,243,000-500,000
Earnings Before Taxes3.2%-114,384,000-118,138,000-115,003,000-107,005,000
EBT Margin-1.6%-382-376--
Net Income2.9%-113,000,000-116,379,000-113,760,000-106,528,000
Net Income Margin-1.3%-378-373--
Free Cashflow-44.5%-126,450,000-87,499,000-87,660,000-103,487,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets11.5%870780852757825664546611701777829853751768782818288345396436462
  Current Assets25.2%386308383275638479370432490508583667605636724783256316367411445
    Cash Equivalents22.4%14111526823054323211810892.0078.0059.0083.0013273.0068.0016153.0019.0039.0077.0054.00
  Inventory69.9%18.0010.009.0010.00-----------------
  Net PPE-2.0%11211411311311010510110110310188.0080.0073.0059.0039.0019.0014.009.006.004.004.00
Liabilities-3.0%19019617817915816415213814915613010810311270.0059.0045.0046.0041.0039.0027.00
  Current Liabilities-24.6%83.0011091.0089.0087.0091.0079.0064.0077.0089.0065.0061.0055.0055.0064.0055.0040.0039.0035.0034.0022.00
Shareholder's Equity16.3%680585674579667500394473552622698744647656712758243299355397435
  Retained Earnings-5.6%-2,125-2,012-1,896-1,782-1,675-1,568-1,463-1,363-1,264-1,172-1,073-986-905-830-761-703-640-570-507-457-410
  Additional Paid-In Capital8.1%2,8052,5942,5792,3602,3432,0691,8591,8391,8181,7951,7711,7311,5531,4871,4731,4618838690.000.00845
Accumulated Depreciation10.7%31.0028.00-------------------
Shares Outstanding9.2%280256256225224188158157157157156151---------
Float----1,400---1,600---3,800---3,700---2,900-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-45.6%-122,279-83,970-84,083-93,967-99,800-77,671-63,649-77,635-73,802-53,849-57,693-54,008-62,391-62,692-40,515-36,635-65,292-53,822-42,182-33,795-29,090
  Share Based Compensation19.3%17,17814,39915,82116,74015,66519,50919,78022,46822,26519,10419,30614,41416,94110,23210,70610,5379,4125,4076,5986,4265,846
Cashflow From Investing-53.1%-111,506-72,845-79,014-156,779153,39646173,71595,76386,51669,33812,748-159,16577,21158,753-52,955-423,756100,10526,8143,49558,6831,033
Cashflow From Financing20022.2%193,576962202,8001,025258,172190,575225-2,0671,4174,15020,772163,98250,3642,9581,166568,4653,8332,0886643,381-2.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IOVA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Operations  
Total revenue$ 715 
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]us-gaap:ProductMemberus-gaap:ProductMember
Costs and expenses  
Cost of sales$ 7,261 
Research and development79,783$ 82,734
Selling, general and administrative31,39328,122
Total costs and expenses118,437110,856
Loss from operations(117,722)(110,856)
Other income  
Interest income, net3,3383,486
Net Loss before income taxes(114,384)(107,370)
Income tax benefit1,4080
Net Loss$ (112,976)$ (107,370)
Net Loss Per Share of Common Stock, Basic$ (0.42)$ (0.50)
Net Loss Per Share of Common Stock, Diluted$ (0.42)$ (0.50)
Weighted Average Shares of Common Stock Outstanding, Basic266,220213,694
Weighted Average Shares of Common Stock Outstanding, Diluted266,220213,694

IOVA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current Assets  
Cash and cash equivalents$ 134,188$ 114,888
Trade accounts receivable234151
Short-term investments222,007164,979
Inventory17,61710,372
Prepaid expenses and other assets11,48717,458
Total Current Assets385,533307,848
Property and equipment, net111,789114,030
Intangible assets, net294,303229,258
Operating lease right-of-use assets71,51662,515
Restricted cash6,43066,430
Long-term assets259270
Total Assets869,830780,351
Current Liabilities  
Accounts payable25,70033,123
Accrued expenses46,43669,406
Operating lease liabilities11,0787,777
Total Current Liabilities83,214110,306
Non-Current Liabilities  
Operating lease liabilities- non-current72,29167,085
Deferred tax liabilities33,30117,347
Long-term note payable1,0001,000
Total Non-Current Liabilities106,59285,432
Total Liabilities189,806195,738
Commitments and contingencies
Stockholders' Equity  
Common stock, $0.000041666 par value; 500,000,000 shares authorized, 279,756,339 and 256,135,715 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively1211
Accumulated other comprehensive loss1162,526
Additional paid-in capital2,805,2442,594,448
Accumulated deficit(2,125,351)(2,012,375)
Total Stockholders' Equity680,024584,613
Total Liabilities and Stockholders' Equity869,830780,351
Series A Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value00
Series B Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value$ 3$ 3
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
 CEO
 WEBSITEiovance.com
 INDUSTRYBiotechnology
 EMPLOYEES503

Iovance Biotherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Iovance Biotherapeutics Inc? What does IOVA stand for in stocks?

IOVA is the stock ticker symbol of Iovance Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Iovance Biotherapeutics Inc (IOVA)?

As of Fri May 17 2024, market cap of Iovance Biotherapeutics Inc is 2.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IOVA stock?

You can check IOVA's fair value in chart for subscribers.

What is the fair value of IOVA stock?

You can check IOVA's fair value in chart for subscribers. The fair value of Iovance Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Iovance Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IOVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Iovance Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether IOVA is over valued or under valued. Whether Iovance Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Iovance Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOVA.

What is Iovance Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, IOVA's PE ratio (Price to Earnings) is -6.37 and Price to Sales (PS) ratio is 2.41 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Iovance Biotherapeutics Inc's stock?

In the past 10 years, Iovance Biotherapeutics Inc has provided 0.045 (multiply by 100 for percentage) rate of return.